Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | TSVT |
---|---|---|
09:32 ET | 8512 | 3.48 |
09:34 ET | 8799 | 3.53 |
09:36 ET | 5648 | 3.54 |
09:38 ET | 1503 | 3.54 |
09:39 ET | 1699 | 3.51 |
09:41 ET | 8592 | 3.52 |
09:43 ET | 100 | 3.53 |
09:45 ET | 475 | 3.51 |
09:48 ET | 4038 | 3.54 |
09:50 ET | 1717 | 3.53 |
09:52 ET | 1200 | 3.55 |
09:54 ET | 2113 | 3.55 |
09:56 ET | 1000 | 3.58 |
09:57 ET | 1000 | 3.585 |
09:59 ET | 600 | 3.595 |
10:01 ET | 1925 | 3.59 |
10:03 ET | 1329 | 3.57 |
10:06 ET | 1100 | 3.59 |
10:08 ET | 3167 | 3.58 |
10:10 ET | 900 | 3.58 |
10:12 ET | 5445 | 3.555 |
10:14 ET | 3347 | 3.55 |
10:15 ET | 9854 | 3.535 |
10:17 ET | 4241 | 3.54 |
10:19 ET | 2825 | 3.55 |
10:21 ET | 4412 | 3.59 |
10:24 ET | 7710 | 3.625 |
10:26 ET | 1321 | 3.6 |
10:28 ET | 4400 | 3.6 |
10:30 ET | 2483 | 3.6305 |
10:32 ET | 4046 | 3.63 |
10:33 ET | 6300 | 3.6499 |
10:35 ET | 5033 | 3.645 |
10:37 ET | 6643 | 3.625 |
10:39 ET | 3500 | 3.605 |
10:42 ET | 6520 | 3.585 |
10:44 ET | 2500 | 3.575 |
10:46 ET | 38714 | 3.55 |
10:48 ET | 296007 | 3.535 |
10:50 ET | 4084 | 3.55 |
10:51 ET | 4802 | 3.545 |
10:53 ET | 15873 | 3.515 |
10:55 ET | 18832 | 3.505 |
10:57 ET | 30168 | 3.46 |
11:00 ET | 10355 | 3.475 |
11:02 ET | 1281 | 3.48 |
11:04 ET | 35124 | 3.475 |
11:06 ET | 100 | 3.475 |
11:08 ET | 2385 | 3.475 |
11:09 ET | 1918 | 3.475 |
11:11 ET | 7657 | 3.47 |
11:13 ET | 9702 | 3.465 |
11:15 ET | 1400 | 3.465 |
11:18 ET | 5032 | 3.445 |
11:20 ET | 200 | 3.445 |
11:22 ET | 400 | 3.445 |
11:24 ET | 158 | 3.445 |
11:26 ET | 6986 | 3.455 |
11:29 ET | 600 | 3.455 |
11:31 ET | 6100 | 3.46 |
11:33 ET | 1700 | 3.455 |
11:36 ET | 300 | 3.455 |
11:38 ET | 225653 | 3.45 |
11:42 ET | 100 | 3.44 |
11:44 ET | 4320 | 3.43 |
11:45 ET | 7200 | 3.42 |
11:47 ET | 3719 | 3.425 |
11:49 ET | 21763 | 3.435 |
11:51 ET | 400 | 3.435 |
11:54 ET | 4602 | 3.43 |
11:56 ET | 500 | 3.425 |
11:58 ET | 2617 | 3.425 |
12:00 ET | 12207 | 3.44 |
12:02 ET | 1799 | 3.46 |
12:03 ET | 5377 | 3.46 |
12:05 ET | 626 | 3.46 |
12:07 ET | 600 | 3.46 |
12:09 ET | 541460 | 3.48 |
12:12 ET | 7703 | 3.5 |
12:14 ET | 1051 | 3.485 |
12:16 ET | 1800 | 3.49 |
12:18 ET | 2866 | 3.5 |
12:20 ET | 300 | 3.485 |
12:21 ET | 6830 | 3.4882 |
12:23 ET | 3099 | 3.49 |
12:25 ET | 150 | 3.495 |
12:27 ET | 100 | 3.495 |
12:32 ET | 2346 | 3.51 |
12:34 ET | 6651 | 3.52 |
12:36 ET | 3523 | 3.52 |
12:38 ET | 2718 | 3.515 |
12:39 ET | 500 | 3.5 |
12:41 ET | 1273 | 3.505 |
12:43 ET | 519986 | 3.495 |
12:45 ET | 700 | 3.5 |
12:48 ET | 18634 | 3.51 |
12:50 ET | 1185 | 3.51 |
12:52 ET | 16081 | 3.53 |
12:54 ET | 20104 | 3.54 |
12:56 ET | 3640 | 3.54 |
12:57 ET | 1740 | 3.55 |
12:59 ET | 100 | 3.545 |
01:01 ET | 3100 | 3.58 |
01:03 ET | 6183 | 3.585 |
01:06 ET | 4337 | 3.57 |
01:08 ET | 1239 | 3.565 |
01:10 ET | 1891 | 3.58 |
01:12 ET | 24645 | 3.595 |
01:14 ET | 6853 | 3.56 |
01:15 ET | 700 | 3.56 |
01:17 ET | 100 | 3.56 |
01:19 ET | 2987 | 3.565 |
01:21 ET | 4963 | 3.57 |
01:24 ET | 1299 | 3.57 |
01:26 ET | 3630 | 3.575 |
01:28 ET | 5799 | 3.6 |
01:30 ET | 1899 | 3.6 |
01:32 ET | 3543 | 3.6 |
01:33 ET | 17825 | 3.6 |
01:35 ET | 2044 | 3.6005 |
01:37 ET | 25774 | 3.605 |
01:39 ET | 400 | 3.605 |
01:42 ET | 400 | 3.605 |
01:44 ET | 169801 | 3.595 |
01:46 ET | 183737 | 3.6 |
01:48 ET | 5796 | 3.5901 |
01:50 ET | 97306 | 3.6 |
01:51 ET | 10673 | 3.595 |
01:53 ET | 2138 | 3.6 |
01:55 ET | 5573 | 3.595 |
01:57 ET | 5816 | 3.6 |
02:00 ET | 33083 | 3.595 |
02:02 ET | 800 | 3.595 |
02:04 ET | 1800 | 3.595 |
02:06 ET | 1000 | 3.59 |
02:08 ET | 16747 | 3.585 |
02:09 ET | 3232 | 3.57 |
02:11 ET | 1738 | 3.585 |
02:13 ET | 300 | 3.58 |
02:15 ET | 100 | 3.585 |
02:18 ET | 200 | 3.58 |
02:20 ET | 8322 | 3.59 |
02:22 ET | 900 | 3.585 |
02:24 ET | 5335 | 3.59 |
02:26 ET | 30468 | 3.565 |
02:27 ET | 3930 | 3.575 |
02:29 ET | 1400 | 3.585 |
02:31 ET | 4274 | 3.59 |
02:33 ET | 2166 | 3.6 |
02:36 ET | 2497 | 3.595 |
02:38 ET | 900 | 3.6 |
02:40 ET | 26152 | 3.62 |
02:42 ET | 1500 | 3.625 |
02:44 ET | 4430 | 3.63 |
02:45 ET | 1100 | 3.64 |
02:47 ET | 600 | 3.63 |
02:49 ET | 4245 | 3.63 |
02:51 ET | 237 | 3.63 |
02:54 ET | 2045 | 3.64 |
02:56 ET | 1810 | 3.645 |
02:58 ET | 5000 | 3.6401 |
03:00 ET | 6111 | 3.64 |
03:02 ET | 4051 | 3.665 |
03:03 ET | 2019 | 3.67 |
03:05 ET | 1473 | 3.675 |
03:07 ET | 17381 | 3.6445 |
03:09 ET | 11024 | 3.645 |
03:12 ET | 14557 | 3.645 |
03:14 ET | 16470 | 3.645 |
03:16 ET | 4290 | 3.645 |
03:18 ET | 9253 | 3.65 |
03:20 ET | 5080 | 3.65 |
03:21 ET | 11730 | 3.645 |
03:23 ET | 10182 | 3.645 |
03:25 ET | 7008 | 3.62 |
03:27 ET | 7908 | 3.605 |
03:30 ET | 8936 | 3.59 |
03:32 ET | 3410 | 3.59 |
03:34 ET | 3115 | 3.58 |
03:36 ET | 11614 | 3.595 |
03:38 ET | 12988 | 3.6 |
03:39 ET | 5200 | 3.575 |
03:41 ET | 17883 | 3.55 |
03:43 ET | 257836 | 3.53 |
03:45 ET | 31002 | 3.55 |
03:48 ET | 7429 | 3.55 |
03:50 ET | 19875 | 3.555 |
03:52 ET | 4746 | 3.535 |
03:54 ET | 18666 | 3.545 |
03:56 ET | 26066 | 3.555 |
03:57 ET | 3788 | 3.55 |
03:59 ET | 269537 | 3.56 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
2Seventy Bio Inc | 179.7M | -0.8x | --- |
Fate Therapeutics Inc | 207.0M | -1.0x | --- |
Enanta Pharmaceuticals Inc | 242.1M | -1.8x | --- |
Selecta Biosciences Inc | 174.9M | -5.0x | --- |
Heron Therapeutics Inc | 139.5M | -0.8x | --- |
Sutro Biopharma Inc | 203.4M | -1.4x | --- |
2seventy bio, Inc. is a cell and gene therapy company, which is focused on the research, development, and commercialization of transformative treatments for cancer. Its approach combines its expertise in T cell engineering technology and lentiviral vector gene delivery approaches, experience in research, development, and manufacturing of cell therapies and a suite of technologies that can be selectively deployed to develop targeted cellular therapies for patients with cancer. The Company’s advancing multiple clinical programs, including SC-DARIC33, for the treatment of pediatric patients with relapsed and refractory acute myeloid leukemia (AML), and bbT369, for the treatment of patients with B-cell non-Hodgkins lymphoma, or B-NHL, as well as multiple preclinical programs, including bbT4015, an engineered CAR T cell therapy targeting MUC16. Additionally, together with its partner Bristol Myers Squibb, the Company is delivering Abecma to multiple myeloma patients in the United States.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $179.7M |
---|---|
Revenue (TTM) | $147.3M |
Shares Outstanding | 50.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-4.27 |
Book Value | $8.19 |
P/E Ratio | -0.8x |
Price/Sales (TTM) | 1.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -132.62% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.